Quick Answer
Lyra Therapeutics, Inc. reported Total Assets of $36.11 million for fiscal year 2025.
Lyra Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $36.11M | -45.6% |
| 2024 | $66.35M | -53.5% |
| 2023 | $142.60M | +29.7% |
| 2022 | $109.97M | +100.4% |
| 2021 | $54.87M | -32.1% |
| 2020 | $80.83M | +440.2% |
| 2019 | $14.96M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $43.71M | -44.5% | -16.9% |
| June 30, 2025 | $52.57M | -44.4% | -6.6% |
| March 31, 2025 | $56.32M | -60.2% | -15.1% |
| December 31, 2024 | $66.35M | -53.5% | -15.8% |
| September 30, 2024 | $78.76M | -34.7% | -16.7% |
| June 30, 2024 | $94.58M | -24.7% | -33.2% |
| March 31, 2024 | $141.53M | +50.8% | -0.8% |
| December 31, 2023 | $142.60M | +29.7% | +18.3% |
- Lyra Therapeutics, Inc. showed a decrease of -45.6% in Total Assets compared to the prior fiscal year.
- Over the 2019–2025 period, Lyra Therapeutics, Inc.’s total assets has grown by 141.3% (from $14.96 million to $36.11 million).
- The most recent figure is from Lyra Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: